Evaluation of The Effect of CXCL9 Levels on Liver Function in Gastrointestinal and Respiratory infections Patients

Abstract

Background: CXCL9, a chemokine stimulated by gamma interferon, is crucial in immunological responses by promoting leukocyte recruitment. Aim: This study investigates the correlation between blood CXCL9 levels and liver function tests in patients with particular respiratory and gastrointestinal diseases, considering potential confounding variables. Methods: A cross-sectional study was performed in Salah AL- Din governorate, Iraq, from December 15, 2023, to July 25, 2024. 320 isolates were obtained from patients diagnosed with asthma, COPD, pneumonia, bronchitis, inflammatory bowel disease, and gastroenteritis disease, ranging in age from 20 to 70 years at the Tikrit Teaching Hospital, the Public Health Laboratory and the Respiratory Chest and Respiratory Diseases consulting clinics. An investigation was conducted on the concentrations of CXCL9 in correlation with many liver enzymes, including alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), and total serum bilirubin (TSB). Results: The research identified a statistically significant correlation between CXCL9 levels and GGT, particularly in those with respiratory dysfunction. GGT levels exhibited considerable variation between males and females, with a statistically significant disparity between the two groups. The results indicate that elevated levels of CXCL9 may be associated with liver dysfunction, particularly in those with respiratory conditions. This study highlights the potential of CXCL9 as a biomarker for hepatic health and its role in inflammatory processes affecting liver function. Future studies should elucidate how CXCL9 affects liver function and explore its therapeutic potential. Body Mass Index (BMI) data could assist in minimising bias in the findings, enhancing our knowledge of the biology of liver illness and facilitating the development of targeted treatments for liver-related problems in afflicted patients.